Agree this should be read as good news for AVXL holders. We really have no idea what level of systems/clinical complexity AVXL staff are dealing with. We do know this ain't your father's Oldsmobile. Like you, I think IF Biogen does link up on an MS deal then that is a MASSIVE message on the AVXL science and overall credibility.